Last updated on August 11, 2026 · Originally published February 16, 2017
You have almost certainly put alpha-bisabolol on your skin. It has been a standard cosmetic ingredient for decades, turning up in sunscreen, moisturiser, cleansers, lipstick and anti-ageing preparations, valued for being gentle on skin that reacts badly to most things.
Which makes it unusual among cannabis terpenes. It is used widely, and its safety on skin at cosmetic concentrations is far better characterised than its role in cannabis. Virtually none of that knowledge tells you what it does when present in the plant.
What it is
Alpha-bisabolol is a monocyclic sesquiterpene alcohol — a colourless, viscous oil most associated with German chamomile, where it is a principal component of the essential oil.
The aroma is lightly floral and faintly sweet, recognisably chamomile. It is nearly insoluble in water, very soluble in ethanol.
Molecular mass: 222.37 g/mol
Boiling point: approximately 300 °C at atmospheric pressure; 153 °C at 12 mmHg
β-Bisabolol is structurally related, differing in the position of the tertiary alcohol group. Most commercial material and nearly all the research concerns the alpha form.
α-Bisabolol itself exists as four stereoisomers, and the distinction matters commercially. The form in German chamomile is (−)-α-bisabolol, sometimes sold as levomenol. Synthetic material is often racemic — a mixture of forms — and an ingredients list rarely tells you which you have.
Chamomile is the familiar source but not the only commercial one. The candeia tree, a Brazilian species, was long harvested for its oil, and bisabolol is also produced synthetically and by fermentation. What ends up in a cosmetic may come from any of these routes.
Why it is in your moisturiser
The cosmetic use is not based on marketing alone. Bisabolol has a reasonable body of work behind its anti-irritant and anti-inflammatory reputation, and a 2011 study went as far as identifying a mechanism: it downregulates the expression of iNOS and COX-2 genes by inhibiting NF-κB and AP-1 signalling, in macrophages exposed to bacterial endotoxin. That is a plausible route by which a compound could reduce inflammatory response, worked out in cell culture.
There is a second reason it appears in formulations. Bisabolol has been studied as a penetration enhancer — a compound that helps another cross the skin barrier — with work going back to a 1991 paper proposing it as a safe option for dermal and transdermal delivery. That has been demonstrated for particular drugs in particular formulations rather than as a general property.
It is worth holding that thought when reading about bisabolol in cannabis topicals. A compound that improves the delivery of another ingredient is doing something real, but that does not mean bisabolol itself produces the intended therapeutic effect.
What the research covers
The rest of the bisabolol literature is preclinical, and more substantial than most minor terpenes manage.
Cancer cell lines. A 2016 study reported that alpha-bisabolol inhibited invasiveness and motility in pancreatic cancer cells through KISS1R activation. A 2012 study found it acted as a proapoptotic agent against BCR-ABL-positive leukemia cells, and — the more interesting part — worked in synergy with imatinib and nilotinib, two established drugs for that disease.
Antibacterial activity, and synergy. A 2010 review gathered the pharmacological work on bisabolol and bisabolol-rich oils, including antibacterial effects. In a 2017 study, direct antibacterial activity required a high concentration; the more notable finding was that α-bisabolol enhanced norfloxacin against one S. aureus strain and gentamicin against one E. coli strain.
Two of those results are worth noticing together, though not for the reason it might seem. In both the leukemia work and the antibacterial work, the more striking finding was not what bisabolol did alone but what it did alongside an established drug. That is a pattern in the results, not a demonstrated mechanism — nothing in these studies connects it to the skin-penetration work, and treating all three as one property would be inventing a link the research does not make.
None of this is clinical evidence. Cell lines and laboratory bacteria are a long way from treatment.
In cannabis
Here is the part that matters for anyone reading a certificate of analysis, and the previous version of this article said it well enough that it is worth keeping.
Bisabolol is generally a minor cannabis terpene, occurring at lower concentrations than myrcene, limonene, β-caryophyllene, pinene or linalool. It is rarely a dominant feature of the terpene profile. The mere presence of alpha-bisabolol on a lab report does not grant palpable anxiety relief, or anything else.
That caution applies with unusual force here, because bisabolol’s reputation was built somewhere else entirely. A compound with decades of topical use at cosmetic concentrations, tested mostly in dishes for other purposes, tells you very little about a trace constituent of inhaled cannabis.
What it does tell you is that the compound is well tolerated on skin at cosmetic concentrations, which is not nothing — but that is a claim about topical use, not about inhalation or ingestion. It is simply a different question from the one people usually ask.
For the wider context, see our guide to cannabis terpenes.
Reviewed by Nani Frenkel, Chief Editor
Updated August 10, 2026. This article was substantially expanded and incorporates material from “Alpha-bisabolol” by Petar Petrov, published September 26, 2018. The description of bisabolol as a phenol has been corrected — it is a sesquiterpene alcohol — along with the physical-property figures and the account of what the research supports.
Originally published February 16, 2017
References
- Kamatou GPP, Viljoen AM. A review of the application and pharmacological properties of α-bisabolol and α-bisabolol-rich oils. J Am Oil Chem Soc. 2010;87(1):1–7. doi:10.1007/s11746-009-1483-3
- Kim S, et al. Inhibitory effects of (−)-α-bisabolol on LPS-induced inflammatory response in RAW264.7 macrophages. Food Chem Toxicol. 2011;49(10):2580–2585. doi:10.1016/j.fct.2011.06.076
- Bonifácio BV, et al. α-Bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with imatinib and nilotinib. PLoS One. 2012;7(10):e46674. doi:10.1371/journal.pone.0046674
- Uno M, et al. α-Bisabolol inhibits invasiveness and motility in pancreatic cancer through KISS1R activation. Anticancer Res. 2016;36(2):583–589. PMID 26851012
- de Sousa Oliveira F, et al. Evaluation of the antibacterial and modulatory potential of α-bisabolol, β-cyclodextrin and α-bisabolol/β-cyclodextrin complex. Biomed Pharmacother. 2017;92:1111–1118. doi:10.1016/j.biopha.2017.06.020
- Kadir R, Barry BW. α-Bisabolol, a possible safe penetration enhancer for dermal and transdermal therapeutics. Int J Pharm. 1991;70(1–2):87–94. doi:10.1016/0378-5173(91)90167-M
- Fiume MM. Bisabolol. Int J Toxicol. 2017;36(5 Suppl 2):24S–25S. doi:10.1177/1091581817716644
image:Pexels, Firdevs
